Media stories about KalVista Pharmaceuticals (NASDAQ:KALV) have been trending somewhat positive on Saturday, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. KalVista Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 46.5730066146708 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of KalVista Pharmaceuticals (NASDAQ KALV) opened at 6.7534 on Friday. The firm’s market capitalization is $65.60 million. The company’s 50-day moving average price is $7.21 and its 200 day moving average price is $7.39. KalVista Pharmaceuticals has a 12-month low of $6.09 and a 12-month high of $10.65.
KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, July 27th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter. The firm had revenue of $0.11 million during the quarter. KalVista Pharmaceuticals had a negative net margin of 5,863.31% and a negative return on equity of 63.41%. On average, equities analysts forecast that KalVista Pharmaceuticals will post ($1.07) earnings per share for the current year.
Separately, ValuEngine raised KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 2nd.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.